Sustained Release for Antiretroviral Treatment or Prevention (SRATP) of HIV Infection (UM1)
The summary for the Sustained Release for Antiretroviral Treatment or Prevention (SRATP) of HIV Infection (UM1) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Sustained Release for Antiretroviral Treatment or Prevention (SRATP) of HIV Infection (UM1): The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications from single institutions and consortia of institutions to participate in the Sustained Release for Antiretroviral Treatment or Prevention (SRATP) of HIV Infection program. Applications may propose development of either treatment or prevention products containing antiretroviral agents delivered using sustained release delivery platforms (oral, injection, implant, transdermal or direct delivery to HIV target mucosa) with the objective of Phase 1 testing before the end of the award. Up to three independent Sustained Release Strategies (SRSs) may be proposed in an application. Each SRS must focus on the development of a separate product. The application must also include one of each of the following Sections: Program Operation Section (POS), Clinical Trial Section (CTS), IND-Enabling Section (IND-ES) and Administrative Coordination Section. Additional Scientific Projects and Scientific Support Sections that will facilitate the achievement of the SRATP sustained release objectives may be included. At least one of the required Sections of the application must include participation by a private sector for-profit or not-for-profit company that will be expected to contribute in a positive and significant way to the overall scientific agenda of the SRATP.
Federal Grant Title: | Sustained Release for Antiretroviral Treatment or Prevention (SRATP) of HIV Infection (UM1) |
Federal Agency Name: | National Institutes of Health |
Grant Categories: | Health Income Security and Social Services |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | RFA-AI-14-008 |
Type of Funding: | Cooperative Agreement |
CFDA Numbers: | 93.242, 93.855, 93.856, 93.865 |
CFDA Descriptions: | Mental Health Research Grants; Allergy, Immunology and Transplantation Research; Microbiology and Infectious Diseases Research; Child Health and Human Development Extramural Research |
Current Application Deadline: | Nov 18, 2014 |
Original Application Deadline: | Nov 18, 2014 |
Posted Date: | May 14, 2014 |
Creation Date: | May 14, 2014 |
Archive Date: | Dec 19, 2014 |
Total Program Funding: | |
Maximum Federal Grant Award: | none |
Minimum Federal Grant Award: | none |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
- Applicants Eligible for this Grant
- Special district governments
For profit organizations other than small businesses
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
County governments
Independent school districts
City or township governments
Public housing authorities/Indian housing authorities
Private institutions of higher education
Small businesses
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
State governments
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Native American tribal organizations (other than Federally recognized tribal governments) - Additional Information on Eligibility
- Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
- Link to Full Grant Announcement
- http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-14-008.html
- Grant Announcement Contact
- NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
National Institutes of Health 301-496-3405 - Similar Government Grants
- • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...
- • Precision Mental Health: Develop Tools to Inform Treatment Selection in Depression (UG3/UH...
- • Interaction between ARVs and Hormones in HIV and Coinfections (R01 Clinical Trial Optional...
- • Strategies for Controlled Release of HIV Vaccines (SCORE-H) (R01 Clinical Trial Not Allowe...
- • Developmental AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optio...
- • Development of Biomarkers for Mental Health Research and Clinical Utilities: (STTR [R41/R4...
- • Development of Biomarkers for Mental Health Research and Clinical Utilities (SBIR [R43/R44...
- • Pharmacologic Agents and Drugs for Mental Disorders (SBIR [R43/R44])
- More Grants from the National Institutes of Health
- • NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed)
- • NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Required)
- • Safety and Early Efficacy Studies of Psychedelic-Assisted Therapy for Chronic Pain in Olde...
- • NIH Pathway to Independence Award (Parent K99/R00 Independent Basic Experimental Studies w...
- • Mentored Research Scientist Development Award (Parent K01 Independent Basic Experimental S...